Upcoming Events

There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.

Past Events

March 13, 2019 • 10:40 am ET

Cowen and Company 39th Annual Health Care Conference

Boston

Webcast

March 12, 2019 • 8:00 am ET

Full-Year 2018 Investor Call and Corporate Update

An archived replay of the call is available through April 12, 2019 and can be accessed by dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415 (International) and providing the Conference ID #13661472.

November 28, 2018 • 12:50 pm ET

Evercore ISI HealthconX

Boston Harbor Hotel, Boston, MA

Webcast

November 15, 2018 • 9:20 am GMT

Jefferies London Healthcare Conference

Waldorf Hilton (Aldwych) Hotel in London

Webcast

November 9 - November 10, 2018

Society for Immunotherapy of Cancer (SITC) Annual Meeting

Hall E, Walter E. Washington Convention Center, Washington, DC

November 7, 2018 • 8:00 am ET

Third Quarter 2018 Financial Results Conference Call

October 3, 2018 • 2:00 pm ET

Leerink Partners Rare Disease & Oncology Roundtable

Lotte New York Palace Hotel, New York, NY

Webcast

October 2, 2018 • 11:30 am ET

Cantor Fitzgerald Global Healthcare Conference

InterContinental New York Barclay Hotel, New York, NY

Webcast

More past events »

Pieris Drug Pipeline

Pieris pipeline includes multiple fully proprietary as well as partnered programs in a number of different therapeutic areas. Our most advanced Anticalin program PRS-080 (hepcidin antagonist to treat anemia), our advanced respiratory program PRS-060 (1st-in-class inhaled IL4Ra antagonist to treat asthma) and several of our immuno-oncology (IO) multispecific programs (PRS-300 series), led by PRS-343 (a HER2/4-1BB bispecific), are examples of our fully proprietary programs. As we continue to build our IO and Respiratory franchises, we aim to ultimately develop Pieris into a fully-integrated pharmaceutical company by retaining commercial rights to several of these programs in major markets. For this purpose, we are also joining forces with other pharmaceutical companies, as exemplified by our strategic co-development IO alliance with Servier, with PRS-332 (PD1-based dual checkpoint inhibitor) as the lead program of this collaboration, to which we retain full US rights.

For more information about our pipeline, click here.

Upcoming Events

Past Events

Q4 2018Quarterly Results

Q3 2018Quarterly Results

Q4 2018
Quarterly Results

Q3 2018
Quarterly Results